back
Food Allergy Essentials
Common Allergens
Food Allergy 101
Allergy Alerts & Ingredient Notices
Back to School Headquarters
Food Allergy & Anaphylaxis Emergency Care Plan
Recipes
Free Downloadable Resources
Information for you
Newly Diagnosed
Children with Food Allergies
Adolescents and Teens
Adults with Allergies
Educators
Healthcare Providers
College Staff
Other Professionals
Join the Community
Join the FARE Community
Find a Support Group

back
Accelerating Innovation
Elevating Care
Pioneering Advances in Diagnosis
Early Introduction and Food Allergy Prevention
Developing Effective Treatments
Elevating Research
FARE Patient Registry
FARE Clinical Network
FARE Data Coordinating Center
FARE Biobank
Clinical Trials
Recently Funded Research
Research Funding Opportunities

Media Room

Releases & Statements

FARE Announces Hy-Vee as Supporter of Teal Pumpkin Project

October 11, 2022

FARE’s Teal Pumpkin Project Welcomes CVS Pharmacy as Exclusive Retail Partner for 2022 Halloween Season

September 20, 2022

FARE and CVS Pharmacy Help Create a More Inclusive and Safe Halloween for All Children

FARE Food Allergy Summit Comes to Orlando

September 19, 2022

FARE Statement Regarding Undeclared Allergens in Chick-fil-A Products

August 26, 2022

FARE Cover Note regarding the FA Collaborative Report on the WH Conference on Hunger, Nutrition and Health

July 25, 2022

Food Allergy Collaborative comments submitted to the 2022 White House Conference on Hunger, Nutrition and Health

July 22, 2022

Statement by Sung Poblete, PhD, RN and CEO of FARE, regarding UnitedHealthcare’s elimination of out-of-pocket costs for several life-saving drugs including epinephrine

July 21, 2022

Weiser Family Gift Provides Generous Support to FARE's New CEO

June 06, 2022

Monies Pledged Will Drive New Research and Initiatives Benefitting the Food Allergy Community

Food Allergy Restaurant Training Bill Unanimously Passes in Westchester County, NY

May 26, 2022

Legislation is a Win-Win for Food Allergy Families and Restaurant Owners

Statement by Sung Poblete, CEO of FARE, regarding FDA’s May 20, 2022 approval of Dupixent (dupilumab) to treat eosinophilic esophagitis (EoE)

May 25, 2022

FARE's Next Decade: The Mission Continues

May 14, 2022

FARE Honors the Teens of the Food Allergy Community

May 13, 2022

Media Contact:

media@foodallergy.org.

About FARE (Food Allergy Research & Education)

FARE (Food Allergy Research & Education) is the leading nonprofit organization that empowers the food allergy patient across their journey of managing the disease. FARE delivers innovation by focusing on three strategic pillars—advocacy, research, and education. FARE’s initiatives accelerate the future of food allergy through effective policies and legislation, novel strategies toward prevention, diagnosis, treatment and a cure, while building awareness and community. To learn more, visit FoodAllergy.org.